Clinical trial
Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With…
NCT00006034 · Intracel, Industry · Completed
Key facts
| NCT number | NCT00006034 |
|---|---|
| Title | Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer |
| Official title | A Randomized, Multicenter Phase III Trial Evaluating the Efficacy and Safety of BCI-ImmuneActivator Versus Adriamycin in BCG Refractory or Intolerant Patients With Carcinoma in Situ With or Without Resected Superficial Papillary Bladder Cancer |
| Lead sponsor | Intracel, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Bladder Cancer |
| Intervention type | Biological, Drug |
| Interventions | keyhole limpet hemocyanin, doxorubicin hydrochloride |
| Start date | Jun 1, 1998 |
| Completion | Mar 1, 2004 |
| First posted | Oct 7, 2003 |
| Last update posted | May 15, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: